Regencell Bioscience Holdings (RGC) Total Liabilities (2020 - 2025)

Regencell Bioscience Holdings has reported Total Liabilities for 6 years, with the latest figure at $1.8 million in Q4 2025.

• For the quarter ending Q4 2025, Total Liabilities changed N/A year-over-year to $1.8 million; the trailing twelve-month figure through Dec 2025 stood at $1.8 million (changed N/A YoY), and the FY2025 full-year result was $895308.0, up 307.86% from the prior year.
• Total Liabilities for Q4 2025 stood at $1.8 million, up from $895308.0 in the prior quarter.
• The five-year high for Total Liabilities was $4.3 million in Q2 2021, with the low at $219512.0 in Q2 2024.
• Historically, Total Liabilities has averaged $1.5 million across 5 years, with a median of $916670.0 in 2022.
• Annual changes were most pronounced in 2022 — Total Liabilities sank 78.38% — and 2025, when it surged 307.86%.
• Regencell Bioscience Holdings' Total Liabilities stood at $4.3 million in 2021, then slumped by 78.38% to $938032.0 in 2022, then sank by 32.59% to $632320.0 in 2023, then tumbled by 65.28% to $219512.0 in 2024, then surged by 717.27% to $1.8 million in 2025.
• The last three Total Liabilities figures came in at $1.8 million (Q4 2025), $895308.0 (Q2 2025), and $219512.0 (Q2 2024), per Business Quant data.